TNFR2 blockade promotes anti-tumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustionAnaïs Debesset(Inserm), José L. Cohen(Inserm)bioRxiv (Cold Spring Harbor Laboratory)January 25, 202410.1101/2024.01.22.573571Cited by 0SaveCiteExport RISWatch citationsRelated PapersNucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression|Cancers|2022|11Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 14, 4265|Cancers|2022|0